

Metsulfuron-methyl
 Milky spore
 Mineral oil
 Muscalure, component of (e)-9-tricosene
 Muscalure, component of (z)-9-tricosene
 N-6-Benzyladenine
 NAA, Ethyl ester
 Nerolidol
 Nicosulfuron
 Nosema locustae
 Octyl bicycloheptenedicarboxamide
 Oxytetracycline hydrochloride
 Paradichlorobenzene
 Paraffin oils
 Periplanone B
 Polyhedral inclusion bodies of *Autographa californica*
 Polyhedral inclusion bodies of *Heliothis zea* NPV or *Helicoverpa zea* NPV
 Polyhedral inclusion bodies of beet armyworm npv
 Polyhedral inclusion bodies, Neodiprion sertifer NVP
 Potassium gibberellate
 Promalin
Pseudomonas cepacia type wiscons.
Pseudomonas fluorescens
Pseudomonas fluorescens A506
Pseudomonas fluorescens EG-1053
Pseudomonas fluorescens strain NCIB 12089
Pseudomonas syringae
Puccinia canaliculata (Schweinitz)
 Rimsulfuron DPX-E9636
Ryania speciosa
 Ryanodine
 s-Kinoprene
 s-Methoprene
 Sesame plant, ground
 Siduron
 Silica gel
 Silicon dioxide
 Sodium carboxymethylcellulose
 Sodium metaborate
 Soybean oil
Streptomyces griseoviridis
 Streptomycin
 Streptomycin sesquisulfate
 Sulfometuron-methyl
 Thifensulfuron-methyl
 Thiobencarb
 Tomato pinworm (e)-4-tridecen-1-yl acetate
 Tomato pinworm (e)-11-tetradecenyl acetate
 Triasulfuron
 1-Triacontanol
Trichoderma harzianum var. *rifai* (KRL-AG2)
Trichoderma harzianum (ATCC 20476)
Trichoderma polysporum (ATCC 20475)
 Tussock moth npv

V. Procedure for Adding Active Ingredients To List

If a registrant believes an active ingredient not on the candidate list meets the criteria set forth in Unit III of this policy statement, and that end use products containing that active ingredient should be eligible for a reduced REI, the registrant should contact EPA at the address given in the FOR FURTHER INFORMATION CONTACT unit, before December 31,

1995. To be considered for a reduced REI, the active ingredient must meet the criteria outlined in this policy, based upon studies determined by the Agency to be acceptable. To use the streamlined notification process, the registrant is required to submit the studies or cite their MRID numbers and provide copies of Agency reviews that confirm that the criteria are met.

If a registrant believes a new active ingredient may meet the criteria set forth in Unit III of this policy statement, the registrant should request that EPA apply the screening criteria for the reduced REI and reference this policy in the application for registration. Registrants having pending applications may also request the reduced 4-hour REI by amending their application for registration. The registrant must also cite this policy and indicate that a reduced REI of 4 hours is being sought. Such pending applications will be considered against the criteria of this policy statement, and, if acceptable, will be permitted the reduced REI. The screening criterion for incident data would not apply to new active ingredients.

If a registrant wishes to add a new WPS use to an existing WPS product, and the active ingredient and product would qualify for a 4-hour REI, the registrant must use the standard label amendment process.

After December 31, 1995, registrants must use the existing label amendment process to request a reduction in a REI. In the future, the Agency will continue to apply the lower toxicity criteria to identify active ingredients which may be eligible for the 4-hour REI during both registration and reregistration process. The Agency will update the list of the candidate active ingredients periodically.

VI. Procedures for Determining Eligibility of End-Use Products

If the registrant wishes to qualify for REI reduction of an end use product(s) that contains any active ingredient(s) included on the candidate list in Unit IV of this policy statement or any subsequent update, the registrant is responsible for determining if that end use product(s) qualifies. To qualify, the following criteria must be met:

1. The end-use product is in Toxicity Category III or IV for all of the following acute toxicity studies: acute dermal toxicity, acute inhalation toxicity, primary skin irritation, and primary eye irritation.

2. Based on the required sensitization or hypersensitivity studies, the end use product is not a sensitizer and there

have been no reports of hypersensitivity.

3. The registrant has no data indicating, and is not aware of, adverse health effects associated with the end use product, e.g., carcinogenicity, neurotoxicity, developmental effects, or reproductive effects.

4. The registrant is not aware and has not been informed of incident information (illness or injury reports) that are "definitely" or "probably" (as defined by the California Incident Reporting System) related to post-application exposures to the product.

VII. Procedure for Notification/Certification

A. Notification Statement

If a registrant determines that an end use product qualifies for a reduced REI, the registrant may notify EPA using the following streamlined notification procedure. The registrant would submit, for each product, to the Agency, Office of Pesticide Programs, Registration Division:

1. An Application for Registration (EPA Form 8570-1), identified as a notification under this policy.

2. One copy of the current product label, clearly marked to highlight the interim WPS REI.

3. Two copies of a revised label, clearly marked to highlight the revised REI.

4. In order to certify to the Agency that the end use product meets all of the criteria outlined above, the registrant must submit the following proof required to demonstrate that the product is eligible for the reduced REI:

i. The registrant must submit the required studies, and cite the MRID numbers for all studies submitted. EPA need not have completed reviews of these studies.

ii. If EPA has permitted the use of studies performed on a substantially similar end use product (analog) to fulfill the acute toxicity data requirements, then the registrant must submit proof that EPA has accepted such data to satisfy end use product data requirements.

iii. If EPA has waived a data requirement for one or more of the required studies, the registrant must submit proof that the requirement for data was waived.

Note: All studies required for evaluating the acute dermal, acute inhalation, eye irritation, skin irritation or skin sensitization/hypersensitization on the end use product must have been submitted, cited, or waived by EPA; only then, can the REI be reduced for the end use product under this notification procedure.